In 20,538 adults with obesity and sleep apnea, tirzepatide showed similar overall clinical outcomes to bariatric surgery but with significantly fewer kidney complications.
40% fewer kidney complications (HR 0.60, p=0.006)While overall outcomes were similar, tirzepatide was associated with significantly fewer major adverse kidney events compared to bariatric surgery in matched patients with obesity and sleep apnea.
What the researchers found
After propensity score matching, 10,269 patients in each group were compared:
- Primary composite outcome (mortality + MACE + MAKE): No significant difference (HR 0.87, 95% CI 0.66-1.15, p = 0.335)
- All-cause mortality: No significant difference (HR 0.90, 95% CI 0.56-1.46, p = 0.672)
- MACE: No significant difference (HR 1.16, 95% CI 0.85-1.56, p = 0.344)
- MAKE (kidney events): Tirzepatide significantly lower (HR 0.60, 95% CI 0.42-0.87, p = 0.006) — a 40% reduction in kidney complications
Why it matters
Bariatric surgery is highly effective for obesity but is invasive, carries surgical risks, and requires permanent anatomical changes. If a peptide injection can achieve similar clinical outcomes — especially with better kidney protection — it fundamentally changes the treatment decision for millions of obese patients with sleep apnea. This study provides the first large-scale head-to-head comparison in this specific population.
How the study worked
Retrospective cohort study using the TriNetX Global Collaborative Network, a multi-institutional electronic health records database. Adults with OSA and comorbid obesity were stratified into tirzepatide and bariatric surgery groups. Propensity score matching balanced baseline characteristics, resulting in 10,269 well-matched patients per group. Primary outcomes were a composite of all-cause mortality, MACE, and MAKE.
What this study cannot tell us
This is a retrospective observational study, not a randomized trial, so residual confounding may exist despite propensity matching. The TriNetX database may not capture all relevant outcomes or follow-up data. The study period for tirzepatide is relatively short (the drug was approved in 2022), so long-term outcomes compared to surgery — which has decades of data — cannot be assessed. Different types of bariatric surgery (sleeve, bypass) were grouped together, though they have different efficacy profiles.
How to read the evidence
This is a large retrospective propensity-matched cohort study using a multi-institutional database. While the sample size (20,538 matched patients) is substantial, the observational design limits causal conclusions compared to a randomized trial.
When this study was published
Published in 2025 using real-world data, this captures the earliest comparative outcomes between tirzepatide and bariatric surgery as the drug enters widespread clinical use.
The bigger picture
The comparison between GLP-1 peptide drugs and bariatric surgery is one of the most important questions in obesity medicine. This study adds to a growing body of evidence that modern peptide drugs can achieve outcomes previously only possible with surgery. The kidney protection advantage is particularly notable, as obesity-related kidney disease is a major and growing problem. As peptide drugs become more effective (with dual and triple agonists), the case for medication over surgery will likely strengthen for many patients.
Questions still open
- Would a randomized controlled trial confirm the kidney protection advantage of tirzepatide over bariatric surgery?
- How do outcomes compare at 5 and 10 years, given that surgery benefits tend to be durable while drug effects require continued treatment?
- Does the kidney protection reflect a direct renal effect of tirzepatide or avoidance of surgical stress and complications?
Common questions
Can tirzepatide really replace bariatric surgery?
Why did tirzepatide protect the kidneys better than surgery?
Read the original research
Comparative clinical outcomes of adults with obstructive sleep apnea and comorbid obesity receiving tirzepatide versus bariatric metabolic surgery: A Multi-Institutional propensity score matched study.
Diabetes research and clinical practice, 226, 112294
Citation
Wu, Jheng-Yan; Lin, Yu-Min; Hsu, Wan-Hsuan; Liu, Ting-Hui; Tsai, Ya-Wen; Huang, Po-Yu; Chuang, Min-Hsiang; Yu, Tsung; Lai, Chih-Cheng. (2025). Comparative clinical outcomes of adults with obstructive sleep apnea and comorbid obesity receiving tirzepatide versus bariatric metabolic surgery: A Multi-Institutional propensity score matched study.. Diabetes research and clinical practice, 226, 112294. https://doi.org/10.1016/j.diabres.2025.112294